Abstracts

 

  • H. I. Brunner, N. Ruperto, D .J. Lovell, G.Horneff, M. Gámir-Gámir, M. Hufnagel,J, Hsu, M. Bao, W. Douglass, N. L. Mallalieu, C. Wells, C. M. Mela, F. De Benedetti.
    Identification of Optimal Subcutaneous Doses of Tocilizumab in Children with Systemic Juvenile Idiopathic Arthritis.
    Arthritis Rheumatol., 70 (Suppl 10), 2018. [ http ]

 

  • H. I. Brunner, N. Ruperto, A. Martini, A. V. Ramanan, R. J. Cuttica, J. E. Weiss, M. Henrickson, H. Schmeling, J. Anton, K. Minden, G.Horneff, M. Gámir-Gámir, M. Hufnagel, W. Douglass, C. Wells, S. Wimalasundera, N. L. Mallalieu, D .J. Lovell and F. De Benedetti.
    Safety of Subcutaneous Tocilizumab Administration in Systemic and Polyarticular Juvenile Idiopathic Arthritis.
    Arthritis Rheumatol., 70 (Suppl 10), 2018. [ http ]

 

  • D. J.  Lovell, N. Ruperto, A. Reiff, L. Jung, K. Jarosova, R. Mouy, I. Koné-Paut, O.Y. Jones, V. Vargova, C. Wouters, I. Galindo, C. Mak, H. I. Brunner and A. Martini.
    Long-Term Disease Control Among Patients with Juvenile Idiopathic Arthritis Receiving Adalimumab (Humira) Treatment for up to Six Years.
    Arthritis Rheumatol., 70 (Suppl 10), 2018. [ http ]

 

  • H. I. Brunner, N. Ruperto, K. Nanda, M. Toth, I. Foeldvari, J. F. Bohnsack, D. Milojevic, D. J. Kingsbury, K. A. Marzan, E. Chalom, G. Horneff, R. M. Kuester, J. A. Dare, M. Trachana, M. Bereswill, H. Kupper, D. Lovell and A. Martini.
    The Safety Profile of Adalimumab across Geographic Regions and Dosing Administrations Among Patients with Juvenile Idiopathic Arthritis Enrolled in a Registry
    Arthritis Rheumatol., 70 (Suppl 10), 2018. [ http ]

 

  • N. Ruperto, H. I. Brunner, G. Vega-Cornejo, A. Berman, R. J. Cuttica, F. Ávila-Zapata, M. Henrickson, D. J. Kingsbury, J. F. Bohnsack, T. Lutz, N. E. Rubio-Perez, V. Gerloni, X. Li, M. Nys, R. Wong, A. Martini and D. J. Lovell.
    Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months by Juvenile Idiopathic Arthritis Disease Category.
    Arthritis Rheumatol., 70 (Suppl 10), 2018. [ http ]

 

  • E. Morgan, A. Consolaro, J. Munro, J. Horonjeff, B. M. Feldman, H. Clairman, C. O. Bingham III, A. Alongi, V. Strand, M. van Rossum, R. Veselý, H. I. Brunner, D Horton, D. J. Lovell, S. Ringold, N. Ruperto, S. Schrandt, N. J. Shiff, K.Toupin-April and B.Shea.
    New Consensus on an Updated Core Domain Set for Clinical Trials in Juvenile Idiopathic Arthritis.
    Arthritis Rheumatol., 70 (Suppl 10), 2018. [ http ]

 

  • N. Ruperto, D. J. Lovell, N. Tzaribachev, A. Zeft, R. Cimaz, V. Stanevica, G. Horneff, J. Bohnsack, T. A. Griffin, R. Carrasco, M. Trachana, J. A. Dare, I. Foeldvari, R. K. Vehe, T. A. Simon, A. Martini and H. I. Brunner.
    Longitudinal Effectiveness of Abatacept in Juvenile Idiopathic Arthritis: Results From an Ongoing JIA Registry. Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018): Lisbon, Portugal. 5-8 September 2018.
    Pediatr Rheumatol Online J, 16 (Suppl 2), 2018. [ http ]

 

  • H. Brunner, N. Ruperto, D. Lovell, I. Calvo-Penedes, G. Horneff, M. Gamir Gamir, M. Hufnagel, J. Hsu, M. Bao, W. Douglass, N. Mallalieu, C. Wells, C. Mela and F. De Benedetti.
    OP0103 Identification of optimal subcutaneous doses of tocilizumab in children with systemic juvenile idiopathic arthritis
    Annals of the Rheumatic Diseases, 77 102-102 (Suppl 2), 2018. [ http ]

 

  • N. Ruperto, H. I. Brunner, N. Tzaribachev, G. Vega-Cornejo, I. Louw, I. Foeldvari, V. Keltsev, M. E. P. Gastanaga, C. Wouters, R. Joos, B. Lauwerys, K. Minden, J. C. Breedt, X. Li, M. Nys, R. Wong, D. J. Lovell and A. Martini.
    Antibody Responses to Diptheria/Tetanus Vaccine in Paediatric Patients with Polyarticular-course Juvenile Idiopathic Arthritis Receiving Subcutaneous Abatacept. Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018): Lisbon, Portugal. 5-8 September 2018.
    Pediatr Rheumatol Online J, 16 (Suppl 2), 2018. [ http ]

 

  • F. Benedetti, N. Ruperto, D. Lovell, G. Horneff, M. Gámir Gámir, M. Hufnagel, J. Hsu, M. Bao, W. Douglass, N. Mallalieu, C. Wells, C. Mela, H. I. Brunner, and PRINTO and PRCSG Investigators.
    Identification of optimal subcutaneous doses of tocilizumab in children with systemic juvenile idiopathic arthritis. Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018): Lisbon, Portugal. 5-8 September 2018.
    Pediatr Rheumatol Online J, 16 (Suppl 2), 2018. [ http ]

 

  • N. Ruperto, H. I. Brunner,  K. Nanda, M. Toth, I. Foeldvari, J. Bohnsack, D. Milojevic, D. J. Kingsbury, K. Marzan, E. Chalom, G. Horneff, R. Kuester, J. Dare, M. Trachana-Pilavaki, M. Bereswill, H. Kupper, A. Martini, and D. Lovell.
    The Safety Profile of Adalimumab Across Geographic Regions and Dosing Administrations Among Patients With Juvenile Idiopathic Arthritis Enrolled in the STRIVE Registry. Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018): Lisbon, Portugal. 5-8 September 2018.
    Pediatr Rheumatol Online J, 16 (Suppl 2), 2018. [ http ]

 

  • T. Simon, M. Bradley, D. Lovell, B. Shakley, C. Zhang, L. Clark, N. Ruperto, D. McDonald, and H. I. Brunner.
    USING ETHNOGRAPHY to Understand Transition in Young Adults with JIA. Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018): Lisbon, Portugal. 5-8 September 2018.
    Pediatr Rheumatol Online J, 16 (Suppl 2), 2018. [ http ]

 

  • N. Ruperto, H. Brunner, N. Tzaribachev, I. Louw, I. Calvo, G. Horneff, M. Henrickson, M. Rama, M. Fischbach, T. Miraval, M. Ally, X. Li, R. Wong, M. Nys, B. Murthy, K. Lin, J. Passarell, A. Martini and D. Lovell.
    THU0549 Absence of association between drug exposure and infection in patients with polyarticular-course juvenile idiopathic arthritis and inadequate response to biologic or non-biologic dmards treated with sc and iv abatacept
    Annals of the Rheumatic Diseases, 77 477-477 (Suppl 2), 2018. [ http ]

 

  • H. I. Brunner, N. Ruperto, Vega-Cornejo, A. Berman, I. Calvo, R. Cuttica, F. Ãvila-Zapata, M. Henrickson, D. Kingsbury, D. Viola, V. Keltsev, K. Minden, J. F. Bohnsack, X. Li, M. Nys, R. Wong, S. Banerjee, D. J. Lovell and A. Martini.
    Subcutaneous Abatacept in Patients Aged 2-17 Years with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Effectiveness, Safety and Immunogenicity over 2 Years
    Arthritis Rheumatol., 69 (suppl 10), 2017. [ http ]

 

  • D. J. Lovell, N. Ruperto, N. Tzaribachev, A. Zeft, R. Cimaz, V. Stanevica, G. Horneff, J. F. Bohnsack, T. A. Griffin, R. Carrasco, M. Trachana, J. A. Dare, I. Foeldvari, R. K. Vehe, T. Simon, H. I. Brunner and A. Martini.
    Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Ongoing Results from the Abatacept in JIA Registry
    Arthritis Rheumatol., 69 (suppl 10), 2017. [ http ]

 

  •   H Brunner, N Ruperto, P Quartier, T Constantin, E Alexeeva, R Schneider, I Kone-Paut, KN Schikler, K Marzan, N Wulffraat, S Padeh, V Chasnyk, C Wouters, JB Kuemmerle-Deschner, T Kallinich, B Lauwerys, E Haddad, EL Nasonov, M Trachana, O Vougiouka, K Leon, A Speziale, K Lheritier, E Vritzali, A Martini and D. Lovell.
    Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study
    Arthritis Rheumatol., 69 (suppl 4) (), . [ http ]

 

  • N. Ruperto, H. Brunner, K. Nanda, M. Toth, I. Foeldvari, J. Bohnsack, D. Milojevic, C. Rabinovich, D. Kingsbury, K. Marzan, P. Quartier, K. Minden, E. Chalom, G. Horneff, R. Kuester, J. Dare, M. Bereswill, J. Kalabic, H. Kupper, A. Martini and D. Lovell.
    THU0525 Safety of adalimumab ± methotrexate for the treatment of polyarticular juvenile idiopathic arthritis (PJIA): strive registry
    Annals of the Rheumatic Diseases, 76 405-405 (Suppl 2), 2017. [ http ]

 

  • N. Ruperto, H. Brunner, N. Tzaribachev, G. Vega-Cornejo, I. Louw, J. Anton, D. Viola, I. Foeldvari, V. Keltsev, D. Kingsbury, C. Wouters, B. Lauwerys, E. Alemao, R. Wong, M. Nys, S. Banerjee, A. Martini and D. Lovell.
    OP0058 Improvement in patient-reported outcomes in patients with polyarticular-course juvenile idiopathic arthritis and inadequate response to biologic or non-biologic disease-modifying antirheumatic drugs treated with sc abatacept
    Annals of the Rheumatic Diseases, 76 75-75 (Suppl 2), 2017. [ http ]

 

  • H Brunner, N Ruperto, K Nanda, M Toth, I Foeldvari, JF Bohnsack, D Milojevic, CE Rabinovich, D Kingsbury, K Marzan, P Quartier, K Minden, E Chalom, G Horneff, RM Kuester, JA Dare, M Bereswill, J Kalabic, H Kupper, DJ Lovell and A. Martini.
    Safety of Adalimumab ± Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA): STRIVE Registry
    Arthritis Rheumatol., 69 (suppl 4) (), 2017. [ http ]

 

  • H Brunner, N Ruperto, P Quartier, T Constantin, E Alexeeva, R Schneider, I Kone-Paut, KN Schikler, K Marzan, N Wulffraat, S Padeh, V Chasnyk, C Wouters, JB Kuemmerle-Deschner, T Kallinich, B Lauwerys, E Haddad, EL Nasonov, M Trachana, O Vougiouka, K Leon, A Speziale, K Lheritier, E Vritzali, A Martini and D. Lovell.
    Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study
    Arthritis Rheumatol., 69 (suppl 4). (), 2017. [ http ]

 

  • H Brunner, N Ruperto, A Martini, A Ramanan, R Cuttica, JE Weiss, M Henrickson, H Schmeling, J Anton, K Minden, J Hsu, K Bharucha, S Wimalasundera, AK Kadva, R Upmanyu, NL Mallalieu, D Lovell and F. De Benedetti.
    Identification of Optimal Subcutaneous Doses of Tocilizumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis
    Arthritis Rheumatol., 69 (suppl 4) (), 2017. [ http ]

 

  • E. Baildam, F. De Benedetti, N. Ruperto, H. Brunner, C. Keane, C. Wells, J. Wang, I. Calvo, R. Cuttica, A. Ravelli, R. Schneider, D. Eleftheriou, C. Wouters, R. Xavier, L. Zemel, R. Burgos-Vargas, P. Dolezalova, S. M. Garay, R. Joos, A. Grom, N. Wulffraat, Z. Zuber, F. Zulian, A. Martini and D. Lovell.
    O43 5-Year Data from Tender, a Phase III Clinical Trial: Safety and Efficacy of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis
    Rheumatology, 55 i56 (suppl_1), 2016. [ http ]

 

  • N. Ruperto, D. Lovell, C. Wallace, M. Toth, I. Foeldvari, J. Bohnsack, D. Milojevic, E. Rabinovich, D. Kingsbury, K. Marzan, P. Quartier, K. Minden, E. Chalom, G. Horneff, R. Kuester, J. Dare, M. Heinrich, H. Kupper, J. Kalabic, A. Martini and H. Brunner.
    THU0216 Safety and Effectiveness of Adalimumabmethotrexate for The Treatment of Polyarticular Juvenile Idiopathic Arthritis (PJIA): Strive Registry
    Annals of the Rheumatic Diseases, 75 266-266 (Suppl 2), 2016. [ http ]

 

  • HI Brunner, N Ruperto, P Quartier, T Constantin, E Alexeeva, I Koné-Paut, K Marzan, N Wulffraat, R Schneider, S Padeh, V Chasnyk, C Wouters, JB Kuemmerle-Deschner, T Kallinich, B Lauwerys, E Haddad, EL Nasonov, M Trachana, O Vougiouka, K Leon, E Vritzali, K Lheritier, A Martini and DJ. Lovell.
    Long-Term Efficacy and Safety of Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results from a PHASE III Extension Study
    Arthritis Rheumatol., 68 (suppl 10) (), 2016. [ http ]

 

  • HI Brunner, N Ruperto, V Keltsev, E Alexeeva, C Abud-Mendoza, H Schmeling, MDR Maldonado-Velázquez, N Rubio-Pérez, M Stanislav, V Chasnyk, D Brown, M Henrickson, D Kingsbury, CE Rabinovich, A Zeft, E Silverman, M Wang, P Charlton, R Lledo-Garcia, L Shaughnessy, DJ Lovell and A Martini.
    A Multi-Center, Open-Label Study to Assess the Pharmacokinetics, Efficacy and Safety of Certolizumab Pegol in Children and Adolescents with Moderately to Severely Active Polyarticular-Course Juvenile Idiopathic Arthritis: Week 24 Results
    Arthritis Rheumatol., 68 (suppl 10) (), 2016. [ http ]

 

  • D Lovell, N Ruperto, N Tzaribachev, G Vega-Cornejo, I Louw, A Berman, I Calvo, R Cuttica, G Horneff, F Avila-Zapata, J Anton, R Cimaz, E Solau-Gervais, R Joos, G Espada, X Li, M Nys, R Wong, S Banerjee, HI Brunner and A. Martini.
    Subcutaneous Abatacept in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety
    Arthritis Rheumatol., 68 (suppl 10) (), 2016. [ http ]

 

  • I Foeldvari, N Ruperto, DJ Lovell, G Horneff, HI Huppertz, P Quartier, G Simonini, M Bereswill, J Kalabic, A Martini and HI. Brunner.
    Uveitis Associated to Polyarticular Juvenile Idiopathic Arthritis
    Arthritis Rheumatol., 68 (suppl 10) (), 2016. [ http ]

 

  • N. Ruperto, H. I. Brunner, A. Hazra, R. Wang, C. Mebus, C. Alvey, M. Lamba, S. Krishnaswami, U. Conte, M. Wang, N. Tzaribachev, I. Foeldvari, G. Horneff, D. Kingsbury, E. Koskova, E. Smolewska, R. K. Vehe, Z. Zuber, A. Martini D. Lovell,
    Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Paediatric Patients from Two To Less than Eighteen Years of Age with Juvenile Idiopathic Arthritis.
    Annals of the Rheumatic Diseases, 75 1202-1203 (Suppl 2), 2016. [ http ]

 

  • N. Ruperto, H. I. Brunner, P. Quartier, T. Constantin, E. Alexeeva, R. Schneider, I. Kone-Paut, K. Schikler, K. Marzan, N. Wulffraat, S. Padeh, V. Chasnyk, C. Wouters, J. B. Kuemmerle-Deschner, T. Kallinich, B. Lauwerys, E. Haddad, E. Nasonov, M. Trachana, O. Vougiouka, K. Leon, A. Speziale, K. Lheritier, A. Martini, D. Lovell on behalf of PRINTO/PRCSG,
    Long-Term Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA): 5-Year Follow-up of An Open-Label Trial.
    Annals of the Rheumatic Diseases, 75 265-266 (Suppl 2), 2016. [ http ]

 

  • N. Ruperto, H. I. Brunner, P. Quartier, T. Constantin, E. Alexeeva, I. Kone-Paut, K. Marzan, N. Wulffraat, R. Schneider, S. Padeh, V. Chasnyk, C. Wouters, J. B. Kuemmerle-Deschner, T. Kallinich, B. Lauwerys, E. Haddad, E. Nasonov, M. Trachana, O. Vougiouka, K. Leon, A. Speziale, K. Lheritier, A. Martini D. Lovell,
    Treating To Target with Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis: Results from The Long-Term Extension The Phase III Pivotal Trial.
    Annals of the Rheumatic Diseases, 75 401-402 (Suppl 2), 2016. [ http ]

 

  • N. Ruperto, D. J. Lovell, C. Wallace, M. Toth, I. Foeldvari, J. Bohnsack, D. Milojevic, E. Rabinovich, D. Kingsbury, K. Marzan, P. Quartier, K. Minden, E. Chalom, G. Horneff, R. M. Kuester, J. Dare, M. Heinrich, H. Kupper, J. Kalabic, A. Martini, H. I. Brunner, on behalf of PRINTO PRCSG,
    Safety and Effectiveness of Adalimumabmethotrexate for The Treatment of Polyarticular Juvenile Idiopathic Arthritis (PJIA): Strive Registry.
    Annals of the Rheumatic Diseases, 75 266 (Suppl 2), 2016. [ http ]

 

  • N. Ruperto, D. J. Lovell, N. Tzaribachev, G. Vega-Cornejo, I. Louw, A. Berman, I. Calvo, R. Cuttica, G. Horneff, F. Avila-Zapata, J. Anton, D. Viola, I. Foeldvari, V. Keltsev, D. Kingsbury, X. Li, M. Nys, R. Wong, S. Banerjee, A. Martini H. I. Brunner,
    Subcutaneous Abatacept in Patients with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response To Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety.
    Annals of the Rheumatic Diseases, 75 138 (Suppl 2), 2016. [ http ]

 

  • Hermine I. Brunner, Nicolino Ruperto, Pierre Quartier, Tamas Constantin, Yackov Berkun, Inmaculada Calvo-Penedes, Mueferet Erguven, Laurence Goffin, Michael Hofer, Tilmann Kallinich et al.,
    Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis Patients Previously Exposed to Biologics.
    Arthritis Rheumatol., 67 (Suppl 10), 2015. [ http ]

 

  • Hermine I. Brunner, Nicolino Ruperto, Pierre Quartier, Tamas Constantin, Ekaterina Alexeeva, Isabelle Kone-Paut, Katherine Marzan, Nico Wulffraat, Rayfel Schneider, Shai Padeh et al.,
    Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis: Results from the Phase 3 Extension Study.
    Arthritis Rheumatol., 67 (Suppl 10), 2015. [ http ]

 

  • Hermine I. Brunner, Nicolino Ruperto, Nikolay Tzaribachev, Zbigniew Zuber, Elena Koskova, Ivan Foeldvari, Eizbieta Smolewska, Gerd Horneff, Charles Mebus, Umberto Conte et al.,
    Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Six to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis.
    Arthritis Rheumatol., 67 (Suppl 10), 2015. [ http ]

 

  • Alexei A. Grom, Hermine I. Brunner, Nicolino Ruperto, Alberto Martini, Daniel Lovell, Virginia Pascual, Karine Lheritier, Karolynn Leon, Ken Abrams Norman Ilowite,
    Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis Patients Treated with Canakinumab: Results from Phase 3 Trial Program.
    Arthritis Rheumatol., 67 (Suppl 10), 2015. [ http ]

 

  • Daniel J. Kingsbury, Pierre Quartier, G. Horneff, Kirsten Minden, Mary Toth, Nupun A. Varothai, Anabela Cardoso Jasmina Kalabic,
    Clinical and Functional Outcomes in Patients with Polyarticular Juvenile Idiopathic Arthritis Following Treatment with Adalimumab.
    Arthritis Rheumatol., 67 (Suppl 10), 2015. [ http ]

 

  • Daniel Lovell, Nicolino Ruperto, Andreas Reiff, Lawrence Jung, Katerina Jarosova, Pierre Quartier, Christy Sandborg, John F. Bohnsack, Dirk Elewaut, Ivan Foeldvari et al.,
    Efficacy and Safety of Adalimumab in Adult Patients with Polyarticular Juvenille Idiopathic Arthritis.
    Arthritis Rheumatol., 67 (Suppl 10), 2015. [ http ]

 

  • Daniel Lovell, Nicolino Ruperto, Daniel J. Kingsbury, Ruben Burgos-Vargas, Tomoyuki Imagawa, G. Horneff, Pierre Quartier, Steven Goodman, Andreas Reiff, Edward H. Giannini et al.,
    Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis.
    Arthritis Rheumatol., 67 (Suppl 10), 2015. [ http ]

 

  • Daniel J. Lovell, N. Ruperto, S. Spalding, J. A. Dare, R. Cimaz, V. Stanevica, R. K. Vehe, N. Tzaribachev, G. Horneff, M. Trachana et al.,
    Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Interim Results from the Abatacept in JIA Registry.
    Arthritis Rheumatol., 67 (Suppl 10), 2015. [ http ]

 

  • A. A. Grom, H. I. Brunner, N. Ruperto, A. Martini, D. Lovell, V. Pascual, K. Lheritier, K. Abrams N. Ilowite,
    Canakinumab in Systemic Juvenile Idiopathic Arthritis: Impact on the Rate and Clinical Presentation of Macrophage Activation Syndrome.
    Ann Rheum Dis, 73(Suppl2) (), 2014. [ http ]

 

  • H. Mirjafari, N. Ruperto, H. I. Brunner, Z. Zuber, F. Zulian, M. R. Maldonado-Velázquez, E. Mantzourani, K. Murray, J. Roth, J. Rovensky, O. Vougiouka, J. Wang, O. Harari, D. Lovell, A. Martini F. De Benedetti,
    A54: Insulin Sensitivity Is Improved in sJIA Children With Insulin Resistance After Tocilizumab Treatment: Results From the TENDER Study .
    Arthritis & Rheumatology, 66 S80-81 (), 2014. [ http ]

 

  • A. Ravelli, N. Ruperto, S. Pederzoli, R. Burgos-Vargas, K. Kobusinska, H. Schmeling, F. Sztajnbok, F. Weller-Heinemann, E. Zholobova, F. Zulian, R. Allen, J. Chaitow, C. Keane, C. Wells, A. Martini, D. J. Lovell F. De Benedetti,
    A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH.
    Arthritis & Rheumatology, 66 S17–S18 (), 2014. [ http ]

 

  • P. Lu, J. Hsu, C. Keane, S. Fettner, J. Wang, N. Ruperto, O. Harari, H. Brunner F. D. Benedetti,
    A171: Tocilizumab Dosing in Juvenile Idiopathic Arthritis: Optimizing for Different Juvenile Idiopathic Arthritis Type and Patient Body Weight. Arthritis & Rheumatology.
    Arthritis & Rheumatology, 66 S222–S223 (), 2014. [ http ]

 

  • F. De Benedetti, N. Ruperto, E. Baildam, R. Burgos-Vargas, G. Horneff, H. I. Huppertz, K. Minden, B. L. Myones, K. Onel, J. Wang, K. N. Bharucha, D. J. Lovell, A. Martini H. Brunner,
    A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis.
    Arthritis & Rheumatology, 66 S23–S24 (), 2014. [ http ]

 

  • T. Dumortier, N. Ruperto, H. I. Brunner O. Luttringer,
    A Pharmacometric-Based Analysis Indicated No Relationship Between Occurrence of Safety Events and Canakinumab Exposure In Systemic Juvenile Idiopathic Arthritis Patients.
    Ann Rheum Dis, 73(Suppl2) (), 2014. [ http ]

 

  • A. Brachat, A. Grom, N. Wulffraat, H. Brunner, P. Quartier, R. Brik, L. McCann, H. Ozdogan, L. Rutkowska-Sak, R. Schneider, V. Gerloni, L. Harel, M. Terreri, K. Houghton, R. Joos, D. Kingsbury, J. Lopez-Benitez, S. Bek, M. Schumacher, M. Valentin, H. Gram, K. Abrams, A. Martini, N. Ruperto, D. Lovell N. Nirmala,
    Changes in Gene Expression and Inflammatory Proteins in Systemic Juvenile Idiopathic Arthritis Patients on Canakinumab Therapy.
    Ann Rheum Dis, 73(Suppl2) (), 2014. [ http ]

 

  • N. M. Wulffraat, N. Ruperto, H. I. Brunner, S. Oliveira, Y. Uziel, K. Nistala, R. Cimaz, M. A. Ferrandiz, B. Flato, M. L. Gamir, I. Koné-Paut, C. Gaillez, K. Lheritier, K. Abrams, A. Martini D. J. Lovell,
    Maintenance of Efficacy by Canakinumab Treatment in Systemic Juvenile Idiopathic Arthritis Patients.
    Ann Rheum Dis, 73(Suppl2) (), 2014. [ http ]

 

  • G. Horneff, N. Ruperto, C. Wallace, M. Bereswill, A. Cardoso, J. Kalabic, H. Kupper H. Brunner,
    Long-term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis.
    Ann Rheum Dis, 73(Suppl2) (), 2014. [ http ]

 

  • D. J. Lovell, N. Ruperto, R. Mouy, E. Paz, N. Rubio-Perez, C. A. Silva, C. Abud-Mendoza, R. Burgos-Vargas, V. Gerloni, J. A. Melo-Gomes, C. S. Magalhaes, J. Chavez-Corrales, C. Huemer, A. J. Kivitz, F. J. Blanco, I. Foeldvari, M. Hofer, H.-I. Huppertz, C. Deslandre, K. Minden, A. J. Block, E. H. Giannini A. Martini,
    A169: Cumulative Long-Term Safety, Efficacy and Patient-Reported Outcomes in Children With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept: Up to 7 Years of Treatment.
    Arthritis & Rheumatology, 66 S218-219 (), 2014. [ http ]

 

  • H. Brunner, N. Ruperto, Z. Zuber, R. J. Cuttica, R. Xavier, I. Calvo, N. Rubio, E. Alekseeva, V. Chasnyk, J. Chavez, G. Horneff, V. Opoka-Winiarska, P. Quartier, A. Spindler, C. Keane, K. N. Bharucha, J. Wang, D. J. Lovell, A. Martini F. De Benedetti,
    A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From CHERISH.
    Arthritis & Rheumatology, 66 S5-6 (), 2014. [ http ]

 

  • F. De Benedetti, N. Ruperto, E. Baildam, R. Burgos-Vargas, G. Horneff, H. I. Huppertz, K. Minden, B. L. Myones, K. Onel, J. Wang, K. N. Bharucha, D. J. Lovell, A. Martini H. Brunner,
    A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis .
    Arthritis & Rheumatology, 66 S23-24 (), 2014. [ http ]

 

  • F. De Benedetti, N. Ruperto, H. Brunner, A. A. Grom, N. Wulffraat, M. Henrickson, R. Jerath, Y. Kimura, A. K. Kadva, J. Wang, A. Martini D. J. Lovell,
    A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study.
    Arthritis & Rheumatology, 66 S8-9 (Suppl 11), 2014. [ http ]

 

  • Francesca Minoia, Sergio Davi, Francesca Bovis, Angela Pistorio, Maurizio Arico, Tadej Avcin, Ed Behrens, Fabrizio De Benedetti, Lisa Filipovich, Alexei Grom, Jan-Inge Henter, AnnaCarin Horne, Norman Ilowite, Michael Jordan, Raju Khubchandani, Toshiyuki Kitoh, Kai Lehmberg, Dan Lovell, Paivi Miettunen, Kim Nichols, Jana Pachlopnik, Seza Ozen, Athimalaipet Ramanan, Ricardo Russo, Rayfel Schneider, Gary Sterba, Carol Wallace, Carine Wouters, Nico Wulffraat, Yosef Uziel, Nicola Ruperto, Alberto Martini, Randy Cron Angelo Ravelli,
    Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Pediatric Rheumatology, 12 O1 (Suppl 1), 2014. [ http ]

 

  • N. Ruperto, H. I. Brunner, I. Kone-Paut, B. Magnusson, S. Ozen, F. Sztajnbok, J. Anton, J. Barash, F. Corona, K. Lheritier, C. Gaillez, A. Martini D. Lovell,
    Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data.
    Pediatric Rheumatology, 12 O12 (Suppl 1), 2014. [ http ]

 

  • F. De Benedetti, N. Ruperto, H. Brunner, A. Grom, N. Wulffraat, M. Henrickson, R. Jerath, Y. Kimura, A. K. Kadva, J. Wang, A. Martini D. Lovell,
    Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study.
    Pediatric Rheumatology, 12 O13 (Suppl 1), 2014. [ http ]

 

  • Daniel Lovell, Anne Johnson, Yuki Kimura, Steve Spalding, Paula Morris, Beth Gottlieb, Karen Onel, Judyann Olson, Barbara Edelheit, Michael Shisov, Lawrence Jung, Elaine Cassidy, Sampath Prahalad, Murray Passo, Tim Beukelman, Jay Mehta, Kara Schmidt, Dirk Foell, Claas Hinze, Bin Huang Edward Giannini,
    Understanding the biology and use of TNF therapy in jia-clinical outcomes.
    Pediatric Rheumatology, 12 P137 (Suppl 1), 2014. [ http ]

 

  • Alessandro Consolaro, Francesca Bovis, Ekaterina Alexeeva, Violeta Panaviene, Jordi Anton, Susan Nielsen, Gordana Susic, Maria Trachana, Troels Herlin, Nico Wulffraat, Pavla Dolezalova, Yosef Uziel, Nahid Shafaie, Ingrida Rumba-Rozenfelde, Valda Stanevicha, Nicolino Ruperto, Daniel Lovell, Angelo Ravelli, Alberto Martini PRINTO,
    Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients.
    Pediatric Rheumatology, 12 P176 (Suppl 1), 2014. [ http ]

 

  • A. Ravelli, H. I. Brunner, N. Ruperto, P. Quartier, A. Consolaro, N. Wulffraat, K. Lheritier, C. Gaillez, A. Martini D. J. Lovell,
    Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA -- an analysis of 12-week pooled data.
    Pediatric Rheumatology, 12 P63 (Suppl 1), 2014. [ http ]

 

  • P. Quartier, A. Grom, N. Ruperto, H. I. Brunner, K. Schikler, M. Erguven, L. Goffin, M. Hofer, T. Kallinich, K. Marzan, C. Gaillez, K. Lheritier, K. Abrams, A. Martini D. J. Lovell,
    Efficacy of canakinumab in biologic-naive versus previously biologic-exposed SJIA patients: a 12-week pooled post-hoc analysis.
    Pediatric Rheumatology, 12 P66 (Suppl 1), 2014. [ http ]

 

  • N. M. Wulffraat, N. Ruperto, H. I. Brunner, S. Oliveira, Y. Uziel, K. Nistala, R. Cimaz, M. A. Ferrandiz, B. Flato, M. Gamir, I. Kone-Paut, C. Gaillez, K. Lheritier, K. Abrams, A. Martini D. Lovell,
    Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients.
    Pediatric Rheumatology, 12 P68 (Suppl 1), 2014. [ http ]

 

  • A. Ravelli, H. I. Brunner, N. Ruperto, P. Quartier, A. Consolaro, N. Wulffraat, K. Lheritier, C. Gaillez, A. Martini D. J. Lovell,
    Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset.
    Pediatric Rheumatology, 12 P69 (Suppl 1), 2014. [ http ]

 

  • Nirit Mor-Vaknin, Miguel Rivas, Maureen Legendre, Y. Yuanfang, Anne Johnson, Bin Huang, Yuki Kimura, Lili Zhao, Steve Spalding, Paula Morris, Beth Gottlieb, Karen Onel, Judyann Olson, Barbara Edelheit, Michael Shishov, Larry Jung, Elaine Cassidy, Sampath Prahalad, Murray Passo, Timothy Beukelman, Jay Mehta, Kara Schmidt, Ed Giannini, Daniel Lovell David Markovitz,
    High levels of DEK autoantibodies may predict early flare following cessation of anti-TNF therapy in juvenile idiopathic arthritis.
    Pediatric Rheumatology, 12 P8 (Suppl 1), 2014. [ http ]

 

  • Nicola Ruperto, Daniel Lovell, Pierre Quartier, Angelo Ravelli, Mahinda Karunaratne, Jasmina Kalabic, Anabela Cardoso, Alberto Martini Gerd Horneff,
    Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: analysis from a phase 3 clinical trial.
    Pediatric Rheumatology, 12 P9 (Suppl 1), 2014. [ http ]

 

  • Claas Hinze, Dirk Foell, Anne Johnson, Yukiko Kimura, Steven J. Spalding, Paula W. Morris, Beth Gottlieb, Karen Onel, Judyann C. Olson, Barbara Edelheit, Michael Shishov, Lawrence Jung, Elaine Cassidy, Sampath Prahalad, Murray H. Passo, Timothy Beukelman, Jay Mehta, Kara M. Schmidt, Edward H. Giannini Daniel J. Lovell,
    A12: The Role of Serum S100A12 Protein Levels in Disease Flare After Withdrawal of Anti-tumor Necrosis Factor Therapy in Polyarticular Forms of Juvenile Idiopathic Arthritis.
    Arthritis & Rheumatology, 66 S19-S20 (), 2014. [ http ]

 

  • Daniel J. Lovell, Anne Johnson, Yuki Kimura, Steven J. Spalding, Paula W. Morris, Beth S. Gottlieb, Karen Onel, Judyann C. Olson, Barbara Edelheit, Michael Shishov, Lawrence Jung, Elaine Cassidy, Sampath Prahalad, Murray H. Passo, Timothy Beukelman, Jay Mehta, Kara M. Schmidt, Dirk Foell, Bin Huang Edward H. Giannini,
    A20: Understanding the Use and Biology of TNF Therapy in JIA-Clinical Outcomes.
    Arthritis & Rheumatology, 66 S31-S32 (), 2014. [ http ]

 

  • Nirit Mor-Vaknin, Miguel Rivas, Maureen Legendre, Cynthia Yuanfan Ye, Anne Johnson, Bin Huang, Lili Zhao, Yuki Kimura, Steven J. Spalding, Paula Morris, Beth Gottlieb, Karen Onel, Judyann C. Olson, Barbara Edelheit, Michael Shishov, Lawrence K. Jung, Elaine Cassidy, Sampath Prahalad, Murray H. Passo, Timothy Beukelman, Jay Mehta, Kara M. Schmidt, Edward H. Giannini, Daniel J. Lovell David Markovitz,
    A44: High Levels of DEK Autoantibodies May Predict Early Flare Following Cessation of Anti-TNF Therapy.
    Arthritis & Rheumatology, 66 S65-S66 (), 2014. [ http ]

 

  • Fabrizio De Benedetti, Hermine Brunner, Nicolino Ruperto, Rayfel Schneider, Ricardo Xavier, Roger Allen, Diane Brown, Jeffrey Chaitow, Manuela Pardeo, Graciela Espada, Valeria Gerloni, Barry Myones, James Frane, Jianmei Wang, Terri H. Lipman, Kamal N. Bharucha, Alberto Martini, Daniel Lovell, the Paediatric Rheumatology International Trials Organisation (PRINTO) Pediatric Rheumatology Collaborative Study Group (PRCSG),
    Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: Results from the TENDER trial.
    Arthritis & Rheumatology, n/a-n/a (), 2014. [ http ]

 

  • Hermine Brunner, Nicolino Ruperto, N. Tzaribachev, Gerd Horneff, Carine Wouters, V. Panaviene, Vyacheslav Chasnyk, Carlos Abud-Mendoza, Ruben Cuttica, Andreas Reiff et al.,
    A148: A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results.
    Arthritis & Rheumatology, 66 S191-S192 (S3), 2014. [ http ]

 

  • Hermine I. Brunner, Nicola Ruperto, Isabelle Kone-Paut, Bo Magnusson, Seza Ozen, Flavio Sztajnbok, Jordi Anton, Judith Barash, Reinhard Berner, Fabrizia Corona et al.,
    An Exploratory Analysis of Predictors of Response from 12-Weeks of Canakinumab Therapy in Patients with Active Systemic Juvenile Idiopathic Arthritis..
    Arthritis Rheumatol., 66 S413-S413 (), 2014. [ http ]

 

  • A. Grom, P. Quartier, N. Ruperto, H. I. Brunner, K. Schikler, M. Erguven, L. Goffin, M. Hofer, T. Kallinich, K. Marzan et al.,
    Canakinumab in Biologic-naive Versus Previously Biologic-Exposed Systemic Juvenile Idiopathic Arthritis Patients: Efficacy Results from a 12 Week Pooled Post Hoc Analysis.
    Arthritis Rheumatol., 66 S999-S999 (), 2014. [ http ]

 

  • A. Ravelli, H. I. Brunner, N. Ruperto, P. Quartier, A. Consolaro, N. Wulffraat, K. Lheritier, C. Gaillez, A. Martini D. J. Lovell,
    Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA-an analysis of 12-week pooled data.
    Pediatric Rheumatology, 12 P63 (Suppl 1), 2014. [ http ]

 

  • L. Sawyer, A. Diamantopoulos, H. Brunner, F. De Benedetti, N. Ruperto, F. Dejonckheere C. Keane,
    Efficacy of Biologic Treatments in Juvenile Idiopathic Arthritis with a Polyarticular Course: and Indirect Comparison.
    Ann Rheum Dis, 72(Suppl3) 740 (), 2013. [ http ]

 

  • L. Sawyer, A. Diamantopoulos, H. Brunner, F. De Benedetti, N. Ruperto, F. Dejonckheere C. Keane,
    Efficacy and Safety of Tocilizumab in Polyarticular Juvenile Idiopathic Arthritis: Cherish Results at Week 40.
    Rheumatology, Volume 52 suppl 1 i33-i43 (), 2013. [ http ]

 

  • Scott Fettner, Peng Lu, Joy Hsu, Caroline Keane, Jianmei Wang, Nicolino Ruperto, Fabrizio De Benedetti Hermine Brunner,
    Pharmacokinetics and pharmacodynamics of long-termtocilizumab therapy in polyarticular juvenile idiopathic arthritis.
    Pharmacotherapy, 33(10) e182-e299 (), 2013. [ http ]

 

  • F. F De Benedetti, N. Ruperto, Z. Zuber, R. Cuttica, R. Xavier, I. Clavo, N. Rubio, E. Alekseeva, V. Chasnyk, J. Chavez, G. Horneff, V. Opoka-Winiarska, P. Quartier, A. Spindler, C. Keane, K. Bharucha, J. Wang, D. Lovell, A. Martini H. I. Brunner,
    Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH.
    Pediatric Rheumatology, 11(Suppl 2) O15 (), 2013. [ http ]

 

  • Hermine I. Brunner, Nicolino Ruperto, Zbigniew Zuber, Rubén J. Cuttica, Ricardo Xavier, Inmaculada Calvo, Nadina Rubio, Ekaterina Alekseeva, Vyacheslav Chasnyk, Jose Chavez, Gerd Horneff, Violetta Opoka-Winiarska, Pierre Quartier, Alberto Spindler, Caroline Keane, Kamal N. Bharucha, Jianmei Wang, Daniel J. Lovell, Alberto Martini Fabrizio De Benedetti,
    Efficacy and Safety Of Tocilizumab In Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From Cherish.
    Arthritis & Rheumatism, 65(Suppl 10) S335 (), 2013. [ http ]

 

  • Nanguneri Nirmala, Nico Wulffraat, Hermine Brunner, Pierre Quartier, Riva Brik, Liza McCann, Huri Ozdogan, Lidia Rutkowska-Sak, Rayfel Schneider, Valeria Gerloni, Liora Harel, Maria Terreri, Kristin Houghton, Rik Joos, Daniel Kingsbury, Jorge M. Lopez-Benitez, Arndt Brachat, Stephan Bek, Martin Schumacher, Marie-Anne Valentin, Hermann Gram, Ken Abrams, Alberto Martini, Nicolino Ruperto Daniel J. Lovell,
    Characterization Of Changes In Gene Expression and Inflammatory Proteins In Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy.
    Arthritis & Rheumatism, 65(Suppl 10) S716 (), 2013. [ http ]

 

  • H. Brunner, P. Quartier, T. Constantin, S. Padeh, I. Calvo, M. Erguven, L. Goffin, M. Hofer, T. Kallinich, S. Oliveira, Y. Uziel, S. Viola, K. Nistala, C. Wouters, K. Lheritier, J. Hruska, K. Abrams, A. Martini, N. Ruperto D. Lovell,
    Canakinumab In The Treatment Of Systemic Juvenile IdiopathicArthritis: Results From a 12-Week Pooled Post-Hoc Analysis ForEfficacy.
    Arthritis & Rheumatism, 65(Suppl 10) S112 (), 2013. [ http ]

 

  • Rayfel Schneider, Hermine I. Brunner, Nicolino Ruperto, Nico Wulffraat, Pierre Quartier, Riva Brik, Liza McCann, Helen E. Foster, Michael Frosch, Valeria Gerloni, Liora Harel, Claudio Len, Kristin Houghton, Rik Joos, Ken Abrams, Karine Lheritier, Sophia Kessabi, Alberto Martini Daniel J. Lovell,
    Marked Improvement In Patient Reported Outcomes Of Children With Active Systemic Juvenile Idiopathic Arthritis With Canakinumab Treatment – Results Of The Phase III Program.
    Arthritis & Rheumatism, 65(Suppl 10) S111 (), 2013. [ http ]

 

  • P. Lu, J. Hsu, C. Keane, S. Fettner, J. Wang, N. Ruperto, O. Harari, H. I. Brunner F. De Benedetti,
    Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients.
    Pediatric Rheumatology, 11(Suppl 2) P171 (), 2013. [ http ]

 

  • N. Ruperto, D. J. Lovell, K. Jarosova, D. Nemcova, V. Vargová, H. Michels, E. C. Chalom, N. Ilowite, C. Wouters, H. I. Brunner, K. K. Kracht, H. Kupper, E. Giannini, A. Martini N. Mozaffarian,
    Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients.
    Pediatric Rheumatology, 11(Suppl 2) O4 (), 2013. [ http ]

 

  • N. Ruperto, H. Brunner, T. Constantin, N. Wulffraat, G. Horneff, J. Anton, R. Berner, F. Corona, R. Cuttica, M. Desjonqueres, M. Fischbach, M. Alessio, A. Chieng, W. Emminger, E. Haddad, K. Lheritier, K. Abrams, J. Hruska, D. Kim, A. Martini D. Lovell,
    Baseline characteristics of patients with active systemic JIA successfully discontinuing corticosteroid while receiving canakinumab: secondary analysis from a pivotal Phase 3 trial.
    Ann Rheum Dis, 72(Suppl 3) 97 (), 2013. [ http ]

 

  • P. Quartier, N. Ruperto, N. Wulffrat, H. Brunner, R. Brik, L. McCann, H. Foster, M. Frosch, V. Gerloni, L. Harel, C. Len, K. Houghton, R. Joos, D. Kim, K. Abrams, K. Lheritier, J. Ricci, A. Martini D. Lovell,
    Canakinumab Improves Health-Related Quality of Life (HRQOL) and Daily Functioning in Systemic Juvinile Idiopathic Arthritis (SJIA) Patients.
    Ann Rheum Dis, 72(Suppl 3) 325 (), 2013. [ http ]

 

  • P. Quartier, N. Ruperto, N. Wulffrat, H. Brunner, R. Brik, L. McCann, H. Foster, M. Frosch, V. Gerloni, L. Harel, C. Len, K. Houghton, R. Joos, K. Abrams, K. Lheritier, S. Kessabi, A. Martini D. Lovell,
    Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients .
    Pediatric Rheumatology, 11(Suppl 2) P170 (), 2013. [ http ]

 

  • P. Quartier, H. Brunner, T. Constantin, S. Padeh, I. Calvo, M. Erguven, L. Goffin, M. Hofer, T. Kallinich, S. Oliveira, Y. Uziel, S. Viola, K. Nistala, C. Wouters, K. Lheritier, J. Hruska, K. Abrams, A. Martini, N. Ruperto D. Lovell,
    Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis.
    Pediatric Rheumatology, 11(Suppl 2) P169 (), 2013. [ http ]

 

  • N. Nirmala, N. Wulffraat, H. Brunner, P. Quartier, R. Brik, L. Mccann, H. Ozdogan, L. Rutkowska-Sak, R. Schneider, V. Gerloni, L. Harel, M. Terreri, K. Houghton, R. Joos, D. Kingsbury, J. Lopez-Benitez, S. Radominski, A. Brachat, S. Bek, M. Schumacher, M. Valentin, H. Gram, K. Abrams, A. Martini, N. Ruperto D. Lovell,
    Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy.
    Pediatric Rheumatology, 11(Suppl 2) P168 (), 2013. [ http ]

 

  • Y. Xiong, W. Wang, V. Ebling, H. Sun, O. Luttringer, K. . Abrams, N. Ruperto H. Brunner,
    Exposure-response modeling of canakinumab in the avoidance of flares in children with systemic juvenile idiopathic arthritis.
    Pediatric Rheumatology, 11(Suppl 2) P181 (), 2013. [ http ]

 

  • C. Malattia, N. Ruperto, E. Palmisani, S. Pederzoli, A. Pistorio, H. I. Brunner, R. Cuttica, I. Calvo, S. M. Garay, D. Eleftheriou, C. Wouters, J. Wang, C. Devlin, D. Lovell, A. Martini, F. De Benedetti A. Ravelli,
    Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial.
    Pediatric Rheumatology, 11(Suppl 2) P147 (), 2013. [ http ]

 

  • F. De Benedetti, H. I. Brunner, E. Baildam, R. Burgos-Vargas, G. Horneff, H. I. Huppertz, K. Minden, B. L. Myones, K. Onel, J. Wang, K. Bharucha, D. Lovell, A. Martini N. Ruperto,
    Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA).
    Pediatric Rheumatology, 11(Suppl 2) P152 (), 2013. [ http ]

 

  • F. De Benedetti, N. Ruperto, H. I. Brunner, A. Grom, N. Wulffraat, M. Henrickson, R. Jerath, Y. Kimura, A. K. Kadva, J. Wang, A. Martini D. Lovell,
    Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study .
    Pediatric Rheumatology, 11(Suppl 2) P151 (), 2013. [ http ]

 

  • H. Mirjafari, N. Ruperto, H. I. Brunner, Z. Zuber, F. Zulian, M. R. Maldonado-Velázquez, E. Mantzourani, K. Murray, J. Roth, J. Rovensky, O. Vougiouka, J. Wang, O. Harari, D. Lovell, A. Martini F. De Benedetti,
    Insulin sensitivity is improved in sjia children with insulin resistance after tocilizumab treatment: results from the tender study.
    Pediatric Rheumatology, 11(Suppl 2) O23 (), 2013. [ http ]

 

  • Fabrizio De Benedetti, Hermine Brunner, Caroline Fettner, Scottand Keane, Clare Devlin Nicolino Wang, Jianmei andRuperto,
    Pharmacokinetics and pharmacodynamics of long-termtocilizumab therapy in patients with systemic juvenile idiopathicarthritis.
    Pharmacotherapy, 33(10) e234 (), 2013. [ http ]

 

  • Scott Fettner, Peng Lu, Joy Hsu, Caroline Keane, Jianmei Wang, Nicolino Ruperto, Fabrizio De Benedetti Hermine Brunner,
    Pharmacokinetics and pharmacodynamics of long-termtocilizumab therapy in polyarticular juvenile idiopathic arthritis.
    Pharmacotherapy, 33(10) e234 (), 2013. [ http ]

 

  • Hermine Brunner, Nicolino Ruperto, Zbigniew Zuber, Caroline Keane, Olivier Harari, Andrew Kenwright, Rube´n J. Cuttica, Vladimir Keltsev, Ricardo Xavier, Inmaculada Calvo Penades, Irina Nikishina, Nadina Rubio-Perez, Ekaterina Alekseeva, Vyacheslav Chasnyk, Jose Chavez, Gerd Horneff, Violetta Opoka-Winiarska, Pierre Quartier, Clovis A. Silva, Earl D. Silverman, Alberto Spindler, D. J. Lovell, Alberto Martini Fabrizio De Benedetti,
    Efficacy and Safety of Tocilizumab in Patients with Polyarticular JuvenileIdiopathic Arthritis: Data From a Phase 3 Trial.
    Arthritis & Rheumatism, 64(10) S682 (), 2012. [ http ]

 

  • Rachel E. Sobel, D. J. Lovell, Hermine I. Brunner, Jennifer E. Weiss, Paula W. Morris, Beth S. Gottlieb, Elizabeth C. Chalom, Lawrence K. Jung, Karen Onel, Lisa Petinoit, Donald P. Goldsmith, Staci Abramsky-Risman, James P. Young Edward H. Giannini,
    Safety of Celecoxib and Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Juvenile Idiopathic Arthritis.
    Arthritis & Rheumatism, 64(10) S489 (), 2012. [ http ]

 

  • Hermine I. Brunner, Nicolino Ruperto, Tamas Quartier, Pierre andConstantin, Nico Wulffraat, Gerd Horneff, Liza Brik, Riva andMcCann, Huri Ozdogan, Lidia Rutkowska-Sak, Yackov Schneider, Rayfel andBerkun, Inmaculada Calvo, Muferet Erguven, Michael Goffin, Laurence andHofer, Tilmann Kallinich, Karine Lheritier, Andrea Abrams, Ken andStancati, D. J. Lovell Alberto Martini,
    Efficacy and Safety of Canakinumab in Patients with Active SystemicJuvenile Idiopathic Arthritis and Fever: Results From Two Pivotal Phase 3 Trials.
    Arthritis & Rheumatism, 64(10) S326 (), 2012. [ http ]

 

  • Nico Wulffraat, Hermine I. Brunner, Nicolino Ruperto, Pierre Quartier, Riva Brik, Liza McCann, Huri Ozdogan, Lidia Rutkowska-Sak, Rayfel Schneider, Valeria Gerloni, Liora Harel, Maria Hilário, Kristin Houghton, Rik Joos, Daniel Kingsbury, Arndt Brachat, Stephan Bek, Martin Schumacher, Marie-Anne Valentin, N. R. Nirmala, Hermann Gram, Ken Abrams, Alberto Martini D. J. Lovell,
    Analysis of Biomarkers in Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy.
    Arthritis & Rheumatism, 64(10) S328 (), 2012. [ http ]

 

  • Hermine Brunner, Nicolino Ruperto, Tamás Constantin, Nico Wulffraat, Gerd Horneff, Jordi Anton, Reinhard Berner, Fabrizia Corona, Rubén J. Cuttica, Marine Desjonqueres, Michel Fischbach, Maria Alessio, Alice Chieng, Wolfgang Emminger, Elie Haddad, Karine Lheritier, Ken Abrams, Josef Hruska, Daniel J. Lovell Alberto Martini,
    Baseline Characteristics Of Patients With Active Systemic JIA On Canakinumab Therapy Successfully Discontinuing Corticosteroids: Secondary Analyses From A Pivotal PHASE 3 Study.
    Arthritis & Rheumatism, 64(10) S113 (), 2012. [ http ]

 

  • Rachel E. Sobel, D. J. Lovell, Hermine I. Brunner, Jennifer E. Weiss, Paula W. Morris, Beth S. Gottlieb, Elizabeth C. Chalom, Lawrence K. Jung, Karen Onel, Lisa Petinoit, Donald P. Goldsmith, Staci Abramsky-Risman, James P. Young Edward H. Giannini,
    Safety of Celecoxib and Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Juvenile Idiopathic Arthritis.
    Arthritis & Rheumatism, 64(10) S489 (), 2012. [ http ]

 

  • F. De Benedetti, N. Ruperto, G. Espada, V. Gerloni, B. Flato, G. Horneff, B. Myones, K. Onel, J. Frane, A. Kenwright, T. H. Lipman, K. N. Bharucha, A. Martini D. Lovell,
    Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: 2-year data from a phase 3 clinical trial.
    Arthritis & Rheumatism, 64(10) 760 (), 2012. [ http ]

 

  • M. Thapa, S. J. Spalding, P. J. Hashkes, S. Ringold, A. S. Zeft, R. P. Sundel, R. K. Otto, E. H. Giannini, D. J. Lovell C. A. Wallace,
    MRI Findings from the Trial of Early Aggressive Therapy (TREAT) Study.
    Proc Am Coll Rheum Pediatric Rheumatology Symposium, (), 2011. [ ]

 

  • R. Mina, M. Rao, S. Powell, J. Pendl, P. G. Melson H. Brunner,
    Predictors for the Effectiveness of Dexamethasone Iontophoresis for the Treatment of TMJ-Involvement in JIA.
    Proc Am Coll Rheum Pediatric Rheumatology Symposium, (), 2011. [ ]

 

  • D. J. Lovell, S. P. Spalding, K. Onel, B. S. Gottlieb, H. I. Brunner, Y. Kimura, P. W. Morris, J. C. Olson, A. Johnson E. H. Giannini,
    Understanding the Biology and Use of Anti-TNF Agents in JIA - Interim Results.
    Proc Am Coll Rheum Pediatric Rheumatology Symposium, (), 2011. [ ]

 

  • C. A. Wallace, E. H. Giannini, S. J. Spalding, P. J. Hashkes, K. M. O'Neil, A. S. Zeft, I. S. Szer, S. M. Ringold, H. Brunner, L. E. Schanberg, R. P. Sundel, D. Milojevic, M. G. Punaro, P. Chira, B. S. Gottlieb, G. C. Higgins, N. T. Ilowite, Y. Kimura, B. Huang D. J. Lovell,
    The Effects of Early Aggressive Therapy in JIA: Results of the TREAT Study.
    Proc Am Coll Rheum Pediatric Rheumatology Symposium, (), 2011. [ ]

 

  • F. De Benedetti, H. Brunner, N. Ruperto, R. Cuttica, C. Malattia, R. Schneider, P. Woo, D. Eleftheriou, E. Baildam, R. Burgos-Vargas, P. Dolezalova, S. M. Garay, R. Joos, N. Wulffraat, Z. Zuber, F. Zulian, C. Wouters, R. M. Xavier, L. Zemel, S. Wright, A. Kenwright, A. Martini D. Lovell,
    Efficacy and Safety of Tocilizumab (TCZ) in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): TENDER 52-Week Data.
    Proc Am Coll Rheum Pediatric Rheumatology Symposium, (), 2011. [ ]

 

  • Daniel J. Lovell, Nicolino Ruperto, Andreas Reiff, Lawrence K. Jung, Gloria Higgins, Isabelle Kone-Paut et al,
    Long-Term Efficacy and Safety of Adalimumab for up to 6 Years in Patients with Juvenile Idiopathic Arthritis.
    Arthritis Rheum 2011, 63 Suppl 10 265 (), 2011. [ ]

 

  • Fabrizio De Benedetti, Hermine Brunner, Roger Allen, Diane Brown, Jeffrey Chaitow, Manuela Pardeo et al,
    Tocilizumab Is Efficacious in Patients with Systemic Juvenile Idiopathic Arthritis Across Baseline Demographic and Disease Characteristics and Prior/Baseline Treatments: 52-Week Data From a Phase 3 Clinical Trial.
    Arthritis Rheum 2011, 63 Suppl 10 2621 (), 2011. [ ]

 

  • Hermine Brunner, Nicolino Ruperto, Gerd Horneff, Pierre Quartier, Tamás Constantin, Berkun Yackov et al,
    Phase III Study Results on the Efficacy and Safety of Canakinumab, a Long-Acting, Fully Human Anti-Interleukin-1 Antibody, in Systemic Juvenile Idiopathic Arthritis with Active Systemic Features.
    Arthritis Rheum 2011, 63 Suppl 10 2622 (), 2011. [ ]

 

  • X. Zhang, P. Morcos, F. De Benedetti, H. Brunner, N. Ruperto, F. Schaefer, S. Roseti, A. Kenwright, A. Martini D. Lovell,
    Pharmacokinetics and Pharmacodynamics of Tocilizumab in Systemic Juvenile Idiopathic Arthritis .
    ACCP (2011) American College of Clinical Pharmacy - Annual Meeting 2011, (), 2011. [ ]

 

  • F. De Benedetti, H. Brunner, N. Ruperto, A. Kenwright, C. Devlin, I. Calvo, Cuttica, Ravelli, Schneider, Eleftheriou, Wouters, Xavier, Zemel, Baildam, Burgos-Vargas, Dolezalova, Garay, Joos, Grom, Wulffraat, Zuber, Zulian, Martini Lovell,
    Efficacy and Safety of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 2-year Data From a Phase 3 Clinical Trial.
    ACR/ARHP (2011) American College of Rheumatology/ARHP Annual Scientific Meeting - 2011 (formerly ACR), (), 2011. [ ]

 

  • A. Zhang, P. N. Morcos, F. De Benedetti, H. Brunner, N. Ruperto, F. Schaefer, S. Roseti, A. Kenwright, A. Martini D. Lovell,
    Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis.
    ASCPT (2011) American Society for Clinical Pharmacology and Therapeutics - 112th Annual Meeting, (), 2011. [ ]

 

  • X. Zhang, P. N. Morcos, F. De Benedetti, H. Brunner, N. Ruperto, F. Schaefer, S. Roseti, A. Kenwright, A. Martini D. Lovell,
    Pharmacokinetics (PK) and Pharmacodynamics (PD) OF Tocilizumab (TCZ) in Systemic Juvenile Idiopathic Arthritis (sJIA).
    EULAR (2011) European League Against Rheumatism 2011, (), 2011. [ ]

 

  • F. De Benedetti, H. Brunner, N. Ruperto, I. Calvo, R. Cuttica, C. Malattia, R. Schneider, P. Woo, C. Wouters, R. Xavier, L. Zemel, S. Wright, A. Kenwright, D. Lovell A. Martini,
    Efficacy and Safety of Tocilizumab (TCZ) in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA): TENDER 52-Week Data.
    EULAR (2011) European League Against Rheumatism 2011, (), 2011. [ ]

 

  • F. De Benedetti, H. Brunner, N. Ruperto, I. Calvo, R. Cuttica, C. Malattia, R. Schneider, P. Woo, C. Wouters, R. Xavier, L. Zemel, S. Wright, A. Kenwright, D. Lovell A. Martini,
    Efficacy and Safety of Tocilizumab (TCZ) in Patients (pts) with Systemic Juvenile Idiopathic Arthritis (sJIA): TENDER 52-Week Data .
    PReS (2011) Paediatric Rheumatology European Society - 18th Congress, (), 2011. [ ]

 

  • S. Visvanathan, C. Wagner, J. Marini, D. J. Lovell, A. Martini, et al , for P. R. I. N. T. O. for P. R. C. S. G. ,
    The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial.
    Pediatric Rheumatology, 8:24 (), 2010. [ http ]

 

  • R. Mina, P. G. Melson, S. Powell, C. H. Hinze, J. Pendl, T. B. Graham H. I. Brunner,
    Effectiveness of Dexamethasone Iontophoresis in Temporomandibular Joint (TMJ)-Arthritis in Juvenile Idiopathic Arthritis (JIA).
    Proceeding of the 17th Pediatric Rheumatology European Society Rheumatology Congress, (), 2010. [ ]

 

  • R. Mina, P. G. Melson, S. Powell, C. H. Hinze, J. Pendl, T. B. Graham H. I. Brunner,
    Effectiveness of Dexamethasone Iontophoresis in Temporomandibular Joint (TMJ)-Arthritis in Juvenile Idiopathic Arthritis (JIA).
    Proceeding of the American College of Rheumatology Annual Meeting, (), 2010. [ ]

 

  • F. De Benedetti, H. Brunner, N. Ruperto, I. Calvo, R. Cuttica, C. Malattia, R. Schneider, P. Woo, C. H. Wouters, R. Xavier, L. S. Zemel, S. Wright, A. Kenwright, A. Martini D. J. Lovell,
    Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis: Efficacy Data from the Placebo-Controlled 12-Week Part of the Phase 3 TENDER Trial.
    Proceeding of the American College of Rheumatology Annual Meeting, (), 2010. [ ]

 

  • F. De Benedetti, H. Brunner, N. Ruperto, S. Wright, A. Kenwright, R. Cuttica, P. Woo, R. Schneider, D. Lovell A. Martini,
    Efficacy and Safety of Tocilizumab In Patients With Systemic Juvenile Idiopathic Arthritis (sJIA): 12-Week Data From The Phase 3 TENDER Trial.
    EULAR (2010) European League Against Rheumatism 2010, (), 2010. [ ]

 

  • A. Zhang, P. N. Morcos, F. De Benedetti, H. Brunner, N. Ruperto, F. Schaefer, S. Roseti, A. Kenwright, A. Martini D. Lovell,
    Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 12-week Data From the Phase 3 TENDER Study.
    EULAR (2010) European League Against Rheumatism 2010, (), 2010. [ ]

 

  • F. De Benedetti, H. Brunner, N. Ruperto, I. Calvo, R. Cuttica, C. Malattia, R. Schneider, P. Woo, C. Wouters, R. Xavier, L. Zemel, S. Wright, A. Kenwright, D. Lovell A. Martini,
    Efficacy and Safety of Tocilizumab (TCZ) in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 12-Week Data From the Phase 3 TENDER Trial.
    PReS (2010) Paediatric Rheumatology European Society - 17th Congress, (), 2010. [ ]

 

  • A. Zhang, H. Brunner, P. N. Morcos, H. I. Huppertz, K. Minden, B. Myones, K. Onel, A. Siammopoulou, C. Silva, A. Kenwright, S. Roseti, F. De Benedetti, D. Lovell, A. Martini N. Ruperto,
    Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 12-week Pharmacokinetics (PK) and Pharmacodynamics (PD) Data from the Phase 3 TENDER Trial.
    PReS (2010) Paediatric Rheumatology European Society - 17th Congress, (), 2010. [ ]

 

  • F. De Benedetti, N. Ruperto, H. Brunner, E. Baildam, R. Burgos, P. Dolezalova, S. M. Garay, J. Gracia-Consuegra, J. Joos, N. Wulffraat, Z. Zuber, F. Zulian, A. Grom, F. Schaefer, S. Wright, A. Kenwright, A. Martini D. Lovell,
    Tocilizumab Improves Systemic and Laboratory Features of Systemic Juvenile Idiopathic Arthritis: 12-Week Data from the Phase 3 TENDER Trial.
    PReS (2010) Paediatric Rheumatology European Society - 17th Congress, (), 2010. [ ]

 

  • N. Ruperto, F. De Benedetti, H. Brunner, R. Allen, D. Brown, J. Chaitow, E. Cortis, G. A. Espada, B. Flato, V. Gerloni, G. Horneff, S. Wright, A. Kenwright, R. Schneider, P. Woo, A. Martini D. Lovell,
    Tocilizumab Is Efficacious in Patients With Systemic Juvenile Idiopathic Arthritis Across Baseline Disease Characteristics and Prior or Baseline Treatments: 12-week Data From the Phase 3 TENDER Trial.
    PReS (2010) Paediatric Rheumatology European Society - 17th Congress, (), 2010. [ ]

 

  • D. J. Lovell, E. H. Giannini, Y. Kimura et al ,
    Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (sJIA).
    Arthr and Rheum, 60 (10) suppl: S 768 (abst #2053) (), 2009. [ ]

 

  • E. Giannini, N. Ilowite D. Lovell,
    Effects of Long-Term Treatment with Etanercept on Growth in Children with Polyarticular Course or Systemic Juvenile Rheumatoid Arthritis.
    Ann Rheum Dis, 68(Suppl 3):308 (), 2009. [ ]

 

  • E. H. Giannini, N. T. Ilowite, D. J. Lovell, C. A. Wallace, E. C. Rabinovich, A. O. Reiff, G. C. Higgins, Y. Chon S. L. Lin,
    The Long-term Safety of Etanercept (Enbrel®) in Children with Polyarticular or Systemic Juvenile Rheumatoid Arthritis..
    Proc Am Coll Rheum Keystone Pediatric Rheumatology Symposium, (), 2008. [ http ]

 

  • A. O. Reiff, D. J. Lovell, N. T. Ilowite, C. A. Wallace, Y. Chon, S. L. Lin, S. W. Baumgartner E. H. Giannini,
    Safety and Efficacy of Over 8 Years of Continuous Etanercept (Enbrel®) Therapy in Patients With Juvenile Rheumatoid Arthritis.
    Proc Am Coll Rheum Pediatric Rheumatology Symposium, (), 2008. [ http ]

 

  • E. H. Giannini, N. T. Ilowite, D. J. Lovell, C. A. Wallace, C. E. Rabinovich, A. O. Reiff, G. Higgins, B. Gottlieb, Y. Chon, S. W. Baumgartner S. L. Lin,
    Safety data from over 1,200 patients-years of methotrexate and/or etanercept treatment in children with polyarticular or systemic juvenile rheumatoid arthritis.
    Proceeding of the 15th Pediatric Rheumatology European Society Rheumatology Congress, 7.5 (), 2008. [ ]

 

  • D. J. Lovell, E. H. Giannini C. A. Wallace,
    Safety over 8 years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis..
    Ann Rheum Dis, 66 112 (), 2007. [ ]

 

  • N. Ruperto, D. J. Lovell, S. Goodman, A. O. Reiff, A. Martini E. H. Giannini,
    Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): Data over two years of treatment in a phase III trial..
    Ann Rheum Dis, 66 185 (), 2007. [ ]

 

  • N. Ruperto, D. J. Lovell, S. Goodman, A. O. Reiff, A. Martini E. H. Giannini,
    Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): Converting from body surface area dosing to fixed dosing in the open-label extension (OLE) of a phase III study..
    Ann Rheum Dis, 66 185 (), 2007. [ ]

 

  • N. Ruperto, E. H. Giannini P. Quartier,
    Re-establishment of clinical benefit in patients with juvenile idiopathic arthritis after abatacept withdrawal and subsequent re-introduction..
    Ann Rheum Dis, 66 436 (), 2007. [ ]

 

  • K. B. Gordon, A. B. Gottlieb, E. H. Giannini, P. J. Mease, J. Li, E. Chi, Y. Chon, H. H. Weng, S. Hamza, J. Wajdula, S. R. Stevens S. L. Lin,
    Clinical trial safety data of events of interest in patients receiving etanercept across approved indications..
    Arthritis Rheum, 56 399-400 (), 2007. [ ]

 

  • N. Ruperto, D. J. Lovell, S. Goodman, A. O. Reiff, D. Nemcova, A. M. Prieur, R. Joos, V. Gerloni, J. Bohnsack, L. Wagner-Weiner, H. I. Huppertz, N. Olson, M. McIlraith, J. Medich, A. Martini E. H. Giannini,
    Two-year efficacy of adalimumab in children with juvenile rheumatoid arthritis (JRA): Results of a phase III trial..
    Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress, 84 (), 2007. [ ]

 

  • N. Ruperto, E. H. Giannini, P. Quartier, N. Rubio-Perez, C. A. Silva, C. Abud, L. Sigal, A. Block, A. Martini D. J. Lovell,
    Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis: Results of a double-blind withdrawal phase..
    Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress, 82-83 (), 2007. [ ]

 

  • D. J. Lovell, E. H. Giannini, Y. Kimura, A. O. Reiff, S. Li, P. J. Hashkes, C. A. Wallace, K. B. Onel, D. R. Nadler, S. A. Biedermann, K. G. Osgood, J. H. Papadopoulos A. R. Radin,
    Preliminary evidence for sustained bioactivity of IL-1 Trap (rilonacept), a long-acting IL-1 inhibitor in systemic juvenile rheumatoid arthritis..
    Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress, 86 (), 2007. [ ]

 

  • N. Ruperto, E. H. Giannini, P. Quartier, N. Rubio-Perez, C. A. Silva, C. Abud, L. Sigal, A. Block, A. Martini D. J. Lovell,
    Re-establishment of clinical benefit in patients with juvenile idiopathic arthritis after abatacept withdrawal and subsequent re-introduction..
    Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress, 166 (), 2007. [ ]

 

  • E. H. Giannini, N. T. Ilowite, D. J. Lovell, C. A. Wallace, C. E. Rabinovich, A. O. Reiff, G. Higgins, Y. Chon S. L. Lin,
    The long-term safety of etanercept in children with polyarticular or systemic juvenile rheumatoid arthritis..
    Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress, 81 (), 2007. [ ]

 

  • R. E. Sobel, D. J. Lovell, E. H. Giannini, N. Sheth, S. Abramsky G. Calkwell,
    A new multi-center registry to monitor long-term safety of non-steroidal anti-inflammatory drugs (NSAIDs) including celebrex in juvenile idiopathic arthritis (JIA)..
    Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress, 193 (), 2007. [ ]

 

  • D. J. Lovell, E. H. Giannini, C. A. Wallace, N. T. Ilowite, A. O. Reiff, Y. Chon, S. L. Lin S. W. Baumgartner,
    Safety and efficacy of over 8 years of continuous etanercept (Enbrel) therapy in patients with juvenile rheumatoid arthritis..
    Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress, 229 (), 2007. [ ]

 

  • N. Ruperto, D. J. Lovell, S. Goodman, A. O. Reiff, L. Jung, K. Jarasova, I. Foeldari, J. Rovensky, K. Minden, R. Vehe, G. H. Horneff, M. McIlraith, J. Medich, A. Martini E. H. Giannini,
    Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): Converting from body surface area dosing to fixed dosing..
    Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress, 176-177 (), 2007. [ ]

 

  • D. J. Lovell, N. Ruperto, A. M. Prieur, E. Paz, N. Rubio-Perez, C. Abud, R. Burgos-Vargas, V. Gerloni, J. A. Melo-Gomes, C. S. Magalhaes, F. Sztajnbok, C. Goldenstein-Schainberg, M. Scheinberg, P. Hashkes, C. Hom, L. H. Sigal, A. J. Block, A. Covucci, P. L. N. Cornet, E. H. Giannini, A. Martini, A. Silva L. Pagliaro,
    Abatacept Treatment of Juvenile Idiopathic Arthritis (JIA): Safety Report.
    Arthritis Rheum, 56 292 (), 2007. [ ]

 

  • E. H. Giannini, N. Ruperto, A. M. Prieur, E. Paz, N. E. Rubio-Perez, C. A. Silva, C. Abud, R. Burgos-Vargas, V. Gerloni, J. Melo-Gomes, C. S. Magalhaes, F. Sztajnbok, C. Goldstein-Schainberg, M. Scheinberg, P. Hashkes, C. Hom, L. H. Sigal, A. J. Block, A. Covucci, D. J. Lovell A. Martini,
    Efficacy of Abatacept in Different Sub-populations of Juvenile Idiopathic Arthritis (JIA): Results of a Randomized Withdrawal Study.
    Arthritis Rheum, 56 291 (), 2007. [ ]

 

  • D. J. Lovell, N. Ruperto, S. Goodman, A. Reiff, D. Nemcova, A. M. Prieur, R. Joos, V. Gerloni, J. Bohnsack, L. Wagner-Weiner, H. I. Huppertz, N. Olson, M. McIlraith, J. Medich, E. H. Giannini A. Martini,
    Adalimumab is Safe and Effective During Long-term Treatment of Patients with Juvenile Rheumatoid Arthritis: Results from a 2-Year Study .
    Arthritis Rheum, 56 292 (), 2007. [ ]

 

  • A. O. Reiff, D. J. Lovell, N. T. Ilowite, C. A. Wallace, Y. Chon, S. L. Lin, S. W. Baumgartner E. H. Giannini,
    Safety and Efficacy of Over 8 Years of Continuous Etanercept (Enbrel) Therapy in Patients With Juvenile Rheumatoid Arthritis.
    Arthritis Rheum, 56 292-293 (), 2007. [ ]

 

  • D. J. Lovell, N. Ruperto, S. Goodman, A. O. Reiff, L. Jung, K. Jarosova, C. Sandborg, I. Foeldvari, J. Rovensky, K. Minden, R. Vehe, G. Horneff, M. McIlraith, J. R. Medich, E. H. Giannini A. Martini,
    Adalimumab for the Treatment of Patients with Juvenile Rheumatoid Arthritis: Safety and Efficacy After Conversion from Body Surface Area-Dosing to Weight-Based Fixed Dosing.
    Arthritis Rheum, 56 373-374 (), 2007. [ ]

 

  • E. H. Giannini, Y. Kimura, S. Li, P. J. Hashkes, A. O. Reiff, C. A. Wallace, K. B. Onel, Yi Wei, W. Fury, D. R. Nadler, S. Biedermann, G. Osgood, J. H. Papadopoulos A. R. Radin,
    Preliminary Evidence for Sustained Bioactivity of IL-1 Trap (Rilonacept), A Long Acting IL-I Inhibitor, In Systemic Juvenile Idiopathic Arthritis (SJIA).
    Arthritis Rheum, 56 514-515 (), 2007. [ ]

 

  • A. J. Block, N. Ruperto, D. J. Lovell, E. H. Giannini A. Martini,
    Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA): Results of a double-blind withdrawal phase..
    Rheumatology, 46 i9-i10 (), 2007. [ ]

 

  • E. H. Giannini, N. T. Ilowite D. J. Lovell,
    The long-term safety of etanercept in children with polyarticular or systemic juvenile rheumatoid arthritis..
    Ann Rheum Dis, 66 550 (), 2007. [ ]

 

  • E. H. Giannini, N. T. Ilowite, D. J. Lovell, C. A. Wallace, C. E. Rabinovich, A. Reiff, T. Bevirt, C. Y. Chen W. H. Tsuji,
    A phase IV registry of etanercept in children with juvenile rheumatoid arthritis..
    Ann Rheum Dis, 65 253-254 (), 2006. [ ]

 

  • V. Visvananthan, J. C. Marini, D. J. Lovell, E. H. Giannini C. Wagner,
    Modulation of inflammatory disease markers after the initiation of infliximab plus methotrexate therapy in patients with juvenile rheumatoid arthritis..
    Ann Rheum Dis, 65 467-468 (), 2006. [ ]

 

  • D. J. Lovell, E. H. Giannini, Y. Kimura A. Radin,
    Preliminary evidence for bioactivity of IL-1 trap (rilonacept), a long-acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis..
    Ann Rheum Dis, 65 693 (), 2006. [ ]

 

  • N. Ruperto, D. J. Lovell, S. Goodman E. H. Giannini,
    48-week data from the study of adalimumab in children with juvenile rheumatoid arthritis (JRA)..
    Ann Rheum Dis, 65 56 (), 2006. [ ]

 

  • N. Ruperto, D. J. Lovell, A. M. Prieur E. H. Giannini,
    Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA)..
    Ann Rheum Dis, 65 248 (), 2006. [ ]

 

  • D. J. Lovell, E. H. Giannini, Y. Kimura, S. Li, P. J. Hashkes, A. O. Reiff, C. A. Wallace, K. B. Onel, D. R. Nadler, J. R. Rosenberg, K. G. Osgood, J. H. Papadopoulos A. R. Radin,
    Preliminary evidence for bioactivity of IL-1 Trap (Rilonacept), a long-acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (SJIA)..
    Arthritis Rheum, 54 S325 (), 2006. [ ]

 

  • E. H. Giannini, N. Ruperto, A. M. Prieur, E. Paz, N. E. R. Perez, C. A. Silva, C. A. Mendoza, R. Burgos-Vargas, C. Saad-Magalhaes, J. A. Melo-Gomes, V. Gerloni, F. Sztajnbok, M. Scheinberg, L. H. Sigal, A. J. Block, A. Covucci, P. L. N. Cornet, L. Pagliaro, D. J. Lovell A. Martini,
    Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA): Results of the double-blind withdrawal phase..
    Arthritis Rheum, 54 4033 (), 2006. [ ]

 

  • D. J. Lovell, N. Ruperto, A. M. Prieur, E. Paz, N. E. R. Perez, C. A. Silva, C. A. Mendoza, R. Burgos-Vargas, C. Magalhaes, J. A. Melo-Gomez, V. Gerloni, F. R. Sztajnbok, M. Scheinburg, L. H. Sigal, A. J. Block, A. Covucci, P. L. N. Cornet, L. Pagliaro, E. H. Giannini A. Martini,
    Assessment of open-label co-stimulation blockade with abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA)..
    Arthritis Rheum, 54 S326 (), 2006. [ ]

 

  • D. J. Lovell, N. Ruperto, L. Jung, A. O. Reiff, D. Nemcova, K. Jarosova, A. M. Prieur, C. Sandborg, J. Rovensky, J. Bohnsack, K. Minden, L. Wagner-Weiner, R. Vehe, G. Horneff, J. Medich, E. H. Giannini A. Martini,
    Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): 48-week results..
    Arthritis Rheum, 54 S303 (), 2006. [ ]

 

  • N. Ruperto, D. J. Lovell, E. H. Giannini A. Martini,
    Comparison of safety, efficacy and pharmacokinetics for 3 and 6 mg/kg infliximab plus methotrexate therapy in JRA patients..
    Clin Exp Rheumatol, 23 S67 (), 2005. [ ]

 

  • N. Ruperto, D. J. Lovell, E. H. Giannini A. Martini,
    Randomized trial of infliximab (IFX) plus methotrexate (MTX) for the treatment of polyarticular juvenile rheumatoid arthritis (JRA)..
    Ann Rheum Dis, 64 511 (), 2005. [ ]

 

  • D. J. Lovell, N. Ruperto, A. Martini E. H. Giannini,
    Comparison of safety, efficacy and pharmacokinetics for 3 and 6 mg/kg infliximab plus methotrexate therapy in JRA patients..
    Arthritis Rheum, 52 S724 (), 2005. [ ]

 

  • V. Visvananthan, E. H. Giannini C. Wagner,
    The effect of infliximab on the modulation of inflammatory disease markers in patients with juvenile rheumatoid arthritis..
    Arthritis Rheum, 52 S86 (), 2005. [ ]

 

  • D. J. Lovell E. H. Giannini,
    Etanercept therapy in children with juvenile rheumatoid arthritis: Four year outcome..
    Clin Exp Rheumatol, 22 522 (), 2004. [ ]

 

  • E. H. Giannini, D. J. Lovell, J. Veith W. Tsuji,
    Study outcomes for etanercept therapy in children with and adolescents with juvenile rheumatoid arthritis (JRA): Update from the pediatric registry..
    Clin Exp Rheumatol, 22 523 (), 2004. [ ]

 

  • E. H. Giannini, D. J. Lovell, N. T. Ilowite, C. A. Wallace, L. E. Schanberg, J. Veith W. Tsuji,
    Safety outcomes from a phase IV pediatric registry: Etanercept (Enbrel) therapy in children and adolescents with juvenile rheumatoid arthritis (JRA)..
    Arthritis Rheum, 50 S90 (), 2004. [ ]

 

  • D. J. Lovell, A. Reiff, O. Y. Jones, R. Schneider, E. H. Giannini, J. B. Whitmore B. White,
    Long-term safety and efficacy experience with etanercept (Enbrel) in children with polyarticular juvenile rheumatoid arthritis..
    Arthritis Rheum, 50 S436 (), 2004. [ ]

 

  • D. J. Lovell, N. Ruperto, S. Goodman, A. Reiff, A. Martini, E. H. Giannini, A. R. Radin, V. S. Rao G. Spencer-Green,
    Preliminary data from the study of adalimumab in children with juvenile idiopathic arthritis (JIA)..
    Arthritis Rheum, 50 S436 (), 2004. [ ]

 

  • E. H. Giannini, N. Ruperto, A. L. Tomasi, V. Gerloni, R. Hafner S. Nielson,
    Neoral registry in polyarticular juvenile rheumatoid arthritis.
    Pediatr Rheumatol, 1 3 (), 2003. [ ]

 

  • E. H. Giannini, D. J. Lovell, T. M. Sherrard, N. T. Ilowite A. Reiff,
    Etanercept/methotrexate registry in juvenile rheumatoid arthritis (JRA).
    Pediatr Rheumatol, 1 3 (), 2003. [ ]

 

  • L. Rider, E. H. Giannini H. I. Brunner,
    Preliminary defintions of improvement for juvenile myositis.
    Arthritis Rheum, 48 S433 (), 2003. [ ]

 

  • N. Ruperto, A. Ravelli, K. J. Murray, E. H. Giannini, D. J. Lovell A. Martini,
    International consensus for core sets of outcome measures for disease activity (DA) and disease damage (DD) assessment. Part I: Juvenile Systemic Lupus Erythematosus (JSLE)..
    Arthritis Rheum, 44 S261 (), 2001. [ ]

 

  • N. Ruperto, K. J. Murray, A. Ravelli, D. J. Lovell, E. H. Giannini A. Martini,
    International consensus for the core sets of outcome measures for disease activity (DA) and disease damage (DD) assessment. Part II: Juvenile Dermatomyositis (JDM).
    Arthritis Rheum, 44 S294 (), 2001. [ ]

 

  • D. J. Lovell, E. H. Giannini, M. Lange, D. Burge B. K. Finck,
    Sustained safety and efficacy of Enbrel (etanercept) in the extended treatment of polyarticular course juvenile rheumatoid arthritis.
    Ann Rheum Dis, 59 724 (), 2000. [ ]

 

  • D. J. Lovell, E. H. Giannini, M. Lange, D. Burge B. K. Finck,
    Safety and efficacy of Enbrel (etanercept) in the extended treatment of polyarticular course juvenile rheumatoid arthritis.
    Arthritis Rheum, (), 1999. [ ]

 

  • D. J. Lovell, E. H. Giannini, M. Lange, L. Soffes B. K. Finck,
    Tumor necrosis factor (P75) receptor Fc fusion protein, TNFR:FC, (Enbrel) in children with polyarticular course juvenile rheumatoid arthritis.
    AAP, S24 (), 1998. [ ]

 

  • D. J. Lovell, E. H. Giannini, J. B. Whitmore, L. Soffes B. K. Finck,
    Safety and Efficacy of tumor necrosis factor receptor P75 Fc fusion protein (TNF:FC, Enbrel) in polyarticular course juvenile rheumatoid arthritis.
    Arthritis Rheum, 41 S130 (), 1998. [ ]

 

  • E. H. Giannini, N. Ruperto, A. Ravelli, E. S. Shear, B. L. Tague, K. Murray, J. E. Levinson, A. Martini D. N. Glass,
    Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis II: Early predictors of outcome.
    Clin Exp Rheumatol, 39 S56 (), 1996. [ ]

 

  • N. Ruperto, J. E. Levinson, A. Ravelli, E. S. Shear, B. L. Tague, K. Tague, K. Murray A. Martini,
    Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis I: Outcome status.
    Arthritis Rheum, 39 S56 (), 1996. [ ]

 

  • N. Ruperto, A. Revelli, J. E. Levinson, E. S. Shear, K. Murray, B. L. Tague, A. Martini, D. N. Glass E. H. Giannini,
    Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis II: Early predictors of outcome.
    Arthritis Rheum, 39 S56 (), 1996. [ ]

 

  • E. H. Giannini, N. Ruperto, A. Ravelli, D. J. Lovell A. Martini,
    Preliminary definition of improvement in juvenile arthritis.
    Arthritis Rheum, 39 S56 (), 1996. [ ]

 

  • D. J. Lovell, E. H. Giannini, L. Rider, J. Hicks, M. Smith, R. Rennebohm C. Lindsley,
    Validation and rater reliability of the childhood myositis assessment scale (C-MAS).
    Arthritis Rheum, 38 S183 (), 1995. [ ]

 

  • E. H. Giannini, E. D. Silverman, D. J. Lovell, R. P. Sundel, B. L. Tague N. Ruperto,
    Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: A double-blind, placebo-controlled pilot study.
    Clin Exp Rheumatol, 13 560 (), 1995. [ ]

 

  • E. H. Giannini, D. J. Lovell, E. D. Silverman R. P. Sundel,
    Intravenous immune globulin in polyarticular JRA: Results of a phase I/II trial.
    Arthritis Rheum, 37 S276 (), 1994. [ ]

 

  • E. H. Giannini, D. J. Lovell, D. T. Felson C. H. Goldsmith,
    Preliminary core set of outcome variables for use in JRA clinical trials.
    Arthritis Rheum, 37 S428 (), 1994. [ ]

 

  • E. H. Giannini D. J. Lovell,
    Redundancy of conventional outcome variables used in JRA clinical trials.
    Arthritis Rheum, 37 S238 (), 1994. [ ]

 

  • E. H. Giannini, A. J. Newman C. W. Fink,
    Low-dose methotrexate in children with JRA: Results of a post-trial, long-term follow-up program.
    Arthritis Rheum, 36 S54 (), 1993. [ ]

 

  • E. D. Silverman, E. H. Giannini G. Cawkwell,
    Intravenous immune globulin in systemic JRA.
    Arthritis Rheum, 36 S59 (), 1993. [ ]

 

  • E. H. Giannini,
    Results of the auranofin long-term follow-up program (AU 109X) in children with juvenile rheumatoid arthritis.
    J Rheumatol, 19 114 (), 1992. [ ]

 

  • E. H. Giannini, E. J. Brewer, A. Shaikov, N. Kuzmina A. Maximov,
    Low-dose methotrexate treatment of recalcitrant JRA: Results of the USA-USSR randomized, controlled trial.
    Arthritis Rheum, S53 S53 (), 1991. [ ]

 

  • E. H. Giannini, A. Shaikov, A. Maximov, N. Kuzmina E. J. Brewer,
    Meta-analysis of anti-rheumatic drug trials in juvenile rheumatoid arthritis.
    Arthritis Rheum, 34 S152 (), 1991. [ ]

 

  • E. H. Giannini, E. J. Brewer, M. L. Scheinbaum, L. A. Alexander R. L. Copp,
    Ibuprofen suspension in the treatment of JRA: Results of a double-blind, aspirin-controlled trial.
    Arthritis Rheum, 32 R39 (), 1989. [ ]

 

  • E. H. Giannini E. J. Brewer,
    Methotrexate in the treatment of recalcitrant JRA: Results of a double-blind, placebo-controlled, randomized trial.
    Arthritis Rheum, 32 S82 (), 1989. [ ]

 

  • E. J. Brewer, N. Kusmina E. H. Giannini,
    Auranofin in the treatment of juvenile rheumatoid arthritis: Results of the USA-USSR, double-blind, placebo-controlled trial.
    Arthritis Rheum, 31 S26 (), 1988. [ ]

 

  • K. A. Sheerin, E. H. Giannini E. J. Brewer,
    HLA B27-associated arthritis in childhood: Long-term clinical and diagnostic outcomes.
    J Allergy Clin Immunol, 81 518 (), 1988. [ ]

 

  • C. W. Fink, E. J. Brewer, N. Kusmina E. H. Giannini,
    Auranofin in the treatment of juvenile rheumatoid arthritis: Results of the USA-USSR, double-blind, placebo-controlled trial.
    SEAPAL, (), 1988. [ ]

 

  • E. J. Brewer E. H. Giannini,
    Oral gold (auranofin) in juvenile rheumatoid arthritis (JRA): Results of a double-blind placebo-controlled trial.
    Arthritis Rheum, 30 S31 (), 1987. [ ]

 

  • E. H. Giannini E. J. Brewer,
    Changes in the erythrocyte sedimentation rate correlate poorly with articular disease activity in JRA.
    J Rheumatol, 13 976 (), 1986. [ ]

 

  • A. Gedalia, E. J. Brewer, E. H. Giannini D. A. Person,
    Joint hypermobility in juvenile episodic arthritis/arthralgia (JEA).
    ILAR, 133 (), 1985. [ ]

 

  • E. J. Brewer, E. H. Giannini, N. Kuzmina L. Alekseev,
    D-penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: Results of a double-blind, placebo-controlled trial.
    ILAR, 50 (), 1985. [ ]

 

  • X. He, E. H. Giannini E. J. Brewer,
    Long-term usage of oral gold (auranofin) in the treatment of children with juvenile rheumatoid arthritis (JRA).
    ILAR, 105 (), 1985. [ ]

 

  • E. J. Brewer, E. H. Giannini, N. Kuzmina L. Alekseev,
    D-penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: Results of a double-blind, placebo-controlled trial.
    Arthritis Rheum, 28 S14 (), 1985. [ ]

 

  • E. H. Giannini E. J. Brewer,
    Characteristics of responders (R) and non-responders (NR) to slower-acting anti-rheumatic drugs (SAARDs) in juvenile rheumatoid arthritis (JRA).
    Arthritis Rheum, 28 S56 (), 1985. [ ]

 

  • E. H. Giannini, E. J. Brewer X. He,
    Auranofin in the long-term treatment of children with juvenile rheumatoid arthritis.
    Clin Res, 33 919a (), 1985. [ ]

 

  • E. H. Giannini E. J. Brewer,
    Generalizations from multiple studies of non-steroidal anti-inflammatory drugs(NSAIDs) in children with juvenile rheumatoid arthritis (JRA).
    Clin Res, 33 918a (), 1985. [ ]

 

  • D. A. Person, G. J. Buffone, C. M. Leatherwood, E. J. Brewer E. H. Giannini,
    Serial determinations of circulating immune complexes (CIC) in the sera of children with rheumatic disease.
    Pediatr Res, 18 306 (), 1984. [ ]

 

  • D. J. Lovell, E. H. Giannini, E. J. Brewer D. A. Person,
    Early clinical indicators of eventual response to non-steroidal anti-inflammatory drugs (NSAIDs) in patients with juvenile rheumatoid arthritis (JRA).
    J Rheumatol, 11 716 (), 1984. [ ]

 

  • A. Gedalia, D. A. Person, E. H. Giannini E. J. Brewer,
    Joint hypermobility in juvenile episodic arthritis/arthralgia (JEA).
    Clin Res, 32 821a (), 1984. [ ]

 

  • E. H. Giannini, E. J. Brewer D. A. Person,
    Auranofin in juvenile rheumatoid arthritis.
    Pediatr Res, 17 419 (), 1983. [ ]

 

  • D. A. Person, C. M. Leatherwood, G. J. Buffone, E. H. Giannini, K. S. Barron E. J. Brewer,
    Immune complexes in the sera of patients with rheumatic disease.
    Pediatr Res, 17 418 (), 1983. [ ]

 

  • E. H. Giannini E. J. Brewer,
    Cooperative multicentered clinical trial with the USSR: Advantages and difficulties..
    Control Clin Trials, 4 151 (NIL), 1983. [ ]

 

  • E. J. Brewer, E. H. Giannini D. A. Person,
    Blood gold concentrations in children with juvenile rheumatoid arthritis.
    Arthritis Rheum, 26 S58 (), 1983. [ ]

 

  • D. J. Lovell, E. H. Giannini, E. J. Brewer D. A. Person,
    Time course response to non-steroidal anti-inflammatory drugs in patients with juvenile rheumatoid arthritis.
    Clin Res, 31 918a (), 1983. [ ]

 

  • D. A. Person, C. M. Leatherwood, G. J. Buffone, E. H. Giannini, K. S. Barron E. J. Brewer,
    Immune complexes in the sera of pediatric patients with rheumatic disease.
    Pediatr Res, 16 229a (), 1982. [ ]

 

  • K. S. Barron, E. J. Brewer E. H. Giannini,
    Children at risk of developing ankylosing spondylitis.
    Arthritis Rheum, 25 S151 (), 1982. [ ]

 

  • E. H. Giannini, E. J. Brewer D. A. Person,
    Auranofin in juvenile rheumatoid arthritis.
    Arthritis Rheum, 25 S17 (), 1982. [ ]

 

  • J. Ivey, E. J. Brewer E. H. Giannini,
    Psychosocial functioning in children with juvenile rheumatoid arthritis (JRA) .
    Arthritis Rheum, 24 100 (), 1981. [ ]

 

  • E. J. Brewer, E. H. Giannini, J. Baum, C. W. Fink, V. Hanson, J. C. Jacobs J. G. Schaller,
    Proquazone in the treatment of juvenile rheumatoid arthritis: A segment I study.
    ILAR, STP6 215 (), 1981. [ ]

 

  • E. J. Brewer, J. C. Bass, E. H. Giannini, B. H. Athreya, D. P. Goldsmith, N. Brandstrup, J. J. Miller L. M. Pachman,
    Pirprofen in the treatment of juvenile rheumatoid arthritis: A segment I study.
    ILAR, 76 (), 1981. [ ]

 

  • D. A. Person, C. M. Leatherwood, E. J. Brewer, E. H. Giannini K. S. Barron,
    Anti-eye antibody in juvenile rheumatoid arthritis.
    Clin Res, 28 863a (), 1980. [ ]

 

  • E. J. Brewer E. H. Giannini,
    A comparative study of the epidemiologic and clinical natural histories of juvenile rheumatoid arthritis.
    Arthritis Rheum, 23 656 (), 1980. [ ]